Welcome to our dedicated page for Vital Farms SEC filings (Ticker: VITL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vital Farms, Inc. filings document operating results, governance matters and material events for a public ethical food company built around pasture-raised eggs and related food products. Form 8-K reports furnish earnings releases, Regulation FD updates, product portfolio actions and exit or disposal activity tied to butter offerings.
Proxy and stockholder-meeting disclosures cover director elections, board structure, executive compensation advisory votes, governance policies and shareholder voting results. Other current reports document board appointments, board leadership transitions, committee service, indemnification arrangements and related corporate-governance matters for the Nasdaq-listed Delaware public benefit corporation.
Vital Farms director Kelly J. Kennedy bought 2,500 shares of common stock in an open-market transaction at a weighted average price of $8.40 per share. After this purchase, Kennedy directly owns 22,927 Vital Farms shares. The trade was executed in multiple transactions priced between $8.28 and $8.40.
Vital Farms, Inc. executive Kathryn McKeon, the company’s CMO and GM, Butter, made an open-market purchase of 604 shares of Vital Farms common stock at $8.28 per share. After this buy, she directly holds 50,275 shares, indicating a modest increase in her personal stake.
Vital Farms, Inc. director William B. Cyr reported an open-market purchase of 6,000 shares of Common Stock. The shares were bought on May 14, 2026 at a weighted average price of $8.52 per share, with individual trade prices ranging from $8.47 to $8.57. Following this transaction, Cyr directly owns 13,794 Vital Farms shares.
Vital Farms, Inc. executive Peter Nicholas Pappas, CSO and President, Eggs, increased his direct stake through both a market purchase and an employee plan acquisition. He bought 3,500 shares of common stock on May 14, 2026 at $8.51 per share in an open-market transaction. On May 15, 2026, he acquired an additional 395 shares at $7.21 per share under the company’s 2020 Employee Stock Purchase Plan, at a price equal to 85% of the closing price on the purchase date. Following these transactions, he directly owns 85,564 shares of Vital Farms common stock.
Vital Farms, Inc. Chief Supply Chain Officer Joseph Michael Holland bought additional company stock in an open-market transaction. On May 14, 2026, he purchased 12,484 shares of common stock at a weighted average price of $8.00 per share, through multiple trades between $7.98 and $8.01. Following this purchase, he directly owns 38,150 shares of Vital Farms common stock.
Vital Farms, Inc. director Denny Marie Post reported an open-market purchase of Common Stock. On May 13, 2026, she bought 3,000 shares at $8.23 per share. Following this transaction, her direct ownership increased to 19,312 shares of Vital Farms common stock.
Vital Farms, Inc. Schedule 13G shows Van Berkom & Associates Inc. reports beneficial ownership of 2,437,508 common shares of Vital Farms, representing 5.44% of the class as of 03/31/2026. The filing lists sole voting and sole dispositive power over the reported shares.
Vital Farms, Inc. reported first quarter 2026 results showing solid sales growth but sharply weaker profitability and a strategic shift in its product portfolio. Net revenue rose 15.4% to $187.2 million, driven by higher volumes, but gross margin fell to 28.3% from 38.5% as oversupply pushed more eggs into lower-priced breaker and wholesale channels.
The company swung to a net loss of $1.5 million, or $0.03 per diluted share, versus net income of $16.9 million a year earlier. Adjusted EBITDA dropped to $5.0 million from $27.5 million. Management decided to wind down the butter business by the end of fiscal 2026 to focus on core egg categories, which it expects to be margin accretive after exit.
Vital Farms ended the quarter with $51.4 million in cash, cash equivalents and marketable securities and no debt, after investing heavily in its Vital Crossroads facility and accelerator farms and repurchasing 1.0 million shares for $20.0 million. For fiscal 2026, it now expects net revenue of $775–$800 million, at least 5% growth over 2025, Adjusted EBITDA of $0–$10 million, and reduced capital expenditures of $70–$75 million.